Hydantoins that modulate BACE-mediated APP processing

Patent metadata

Field	Value
Publication number	US-9926280-B2
Application number	US-201514928775-A
Country	US
Kind code	B2
Filing date	Oct 30, 2015
Priority date	Feb 12, 2013
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.

First claim

What is claimed is:

1. A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof, a tautomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt of an enantiomer thereof.

2. The compound of claim 1 , wherein said compound is a compound according to the formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein said compound is capable of binding to APP and/or to the enzyme BACE and/or to an APP/BACE complex.

4. The compound of claim 1 , wherein said compound is capable of binding to APP and inhibiting the enzyme BACE.

5. A kit comprising one or more containers containing a compound of claim 1 .

6. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

7. The formulation of claim 6 , wherein said formulation is compounded for administration via a route selected from the group consisting of oral delivery, isophoretic delivery, transdermal delivery, parenteral delivery, aerosol administration, administration via inhalation, intravenous administration, and rectal administration.

8. The formulation of claim 6 , wherein said formulation is compounded for oral administration.

9. The formulation of claim 6 , wherein said formulation is sterile.

10. The formulation of claim 6 , wherein said formulation is a unit dosage formulation.

11. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a compound according to the formula:

12. The formulation of claim 11 , wherein said formulation is compounded for administration via a route selected from the group consisting of oral delivery, isophoretic delivery, transdermal delivery, parenteral delivery, aerosol administration, administration via inhalation, intravenous administration, and rectal administration.

13. The formulation of claim 11 , wherein said formulation is compounded for oral administration.

14. The formulation of claim 11 , wherein said formulation is sterile.

15. The formulation of claim 11 , wherein said formulation is a unit dosage formulation.

16. A compound of Formula VI:

or a pharmaceutically acceptable salt thereof, a tautomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt of an enantiomer thereof.

Assignees

• Buck Inst Res Aging

Inventors

• John Varghese
• Bredesen Dale E

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title